Literature DB >> 19410615

Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.

Mritunjay Pandey1, Anupom Borah, Merina Varghese, Pijus Kanti Barman, Kochupurackal P Mohanakumar, Rajamma Usha.   

Abstract

We tested the hypothesis that dopamine contributes significantly to the hydroxyl radical (OH)-induced striatal neurotoxicity caused by 3-nitropropionic acid (3-NP) in a rat model of Huntington's disease. Dopamine (10-100 microM) or 3-NP (10-1000 microM) individually caused a significant increase in the generation of hydroxyl radical (OH) in the mitochondria, which was synergistically enhanced when the lowest dose of the neurotoxin (10 microM) and dopamine (100 microM) were present together. Similarly, systemic administration of l-DOPA (100-250 mg/kg) and a low dose of 3-NP (10 mg/kg) potentiated OH generation in the striatum, and the rats exhibited significant decrease in stride length, a direct indication of neuropathology. The pathology was also evident in striatal sections subjected to NeuN immunohistochemistry. The significant changes in stride length, the production of striatal OH and neuropathological features due to administration of a toxic dose of 3-NP (20 mg/kg) were significantly attenuated by treating the rats with tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine prior to 3-NP administration. These results strongly implicate a major contributory role of striatal dopamine in increased generation of OH, which leads to striatal neurodegeneration and accompanied behavioral changes, in 3-NP model of Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410615     DOI: 10.1016/j.neuint.2009.04.013

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  5 in total

1.  Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat.

Authors:  G Akopian; C Crawford; G Petzinger; M W Jakowec; J P Walsh
Journal:  Neuroscience       Date:  2012-04-30       Impact factor: 3.590

Review 2.  Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease.

Authors:  Mritunjay Pandey; Kochupurackal P Mohanakumar; Rajamma Usha
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 3.  A mitochondrial basis for Huntington's disease: therapeutic prospects.

Authors:  J Chakraborty; U Rajamma; K P Mohanakumar
Journal:  Mol Cell Biochem       Date:  2013-12-29       Impact factor: 3.396

4.  Alleviation of Huntington pathology in mice by oral administration of food additive glyceryl tribenzoate.

Authors:  Debashis Dutta; Moumita Majumder; Ramesh Kumar Paidi; Kalipada Pahan
Journal:  Neurobiol Dis       Date:  2021-02-24       Impact factor: 7.046

Review 5.  3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future.

Authors:  Isaac Túnez; Inmaculada Tasset; Verónica Pérez-De La Cruz; Abel Santamaría
Journal:  Molecules       Date:  2010-02-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.